Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 20/20 | 0.82 |
| ▸ | ADRB1 | P08588 | 20/20 | 0.82 |
| ▸ | DRD3 | P35462 | 5/20 | 0.82 |
| ▸ | DRD2 | P14416 | 8/20 | 0.75 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5120384 | 0.88 | ADRB2 (0.87) | ADRB2ADRB1DRD3DRD2ADRA1D | |
| SCHEMBL5126179 | 0.88 | ADRB2 (0.87) | ADRB2ADRB1DRD3DRD2ADRA1D | |
| SCHEMBL12619713 | 0.86 | ADRB2 (1.00) | ADRB2ADRB1DRD3DRD2ADRA1D | |
| Formic Acid SCHEMBL5127981 | 0.85 | ADRB2 (0.83) | ADRB2ADRB1DRD3DRD2ADRA1D | |
| Formic Acid SCHEMBL5119445 | 0.85 | ADRB2 (0.83) | ADRB2ADRB1DRD3DRD2ADRA1D | |
| SCHEMBL4526989 | 0.83 | ADRB2 (1.00) | ADRB2ADRB1DRD3DRD2ADRA1D | |
| SCHEMBL1800392 | 0.82 | ADRB2 (1.00) | ADRB2ADRB1DRD3DRD2ADRA1D | |
| SCHEMBL1800389 | 0.82 | ADRB2 (1.00) | ADRB2ADRB1DRD3DRD2ADRA1D | |
| SCHEMBL4218708 | 0.82 | ADRB2 (0.95) | ADRB2ADRB1DRD3DRD2ADRA1D | |
| SCHEMBL3833821 | 0.82 | ADRB2 (0.56) | ADRB2ADRB1DRD3DRD2ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1529038-B1 | BENZOTHIAZOLE DERIVATIVES HAVING BETA-2-ADRENORECEPTOR AGONIST ACTIVITY | NOVARTIS AG (CH) | 2009-10-07 | — | — | EP | claimed |
| US-20080267886-A1 | Such as 8-hydroxy-5-[1-hydroxy-2-(indan-2-ylamino)-ethyl]-1H-quinolin-2-one; for treatment of inflammatory or obstructive airways diseases | NOVARTIS AG (CH) | 2008-10-30 | — | — | US | claimed |
| JP-2007538036-A | — | — | 2007-12-27 | — | — | JP | claimed |
| EP-1755590-A1 | COMBINATIONS OF GLYCOPYRROLATE AND BETA2 ADRENOCEPTOR AGONISTS | Novartis AG (CH) | 2007-02-28 | — | — | EP | claimed |
| EP-1715860-A1 | COMBINATION OF BENZOTHIAZOL-2-ONE BETA2 ADRENOCEPTOR AGONISTS AND CORTICOSTEROIDS FOR THE TREATMENT OF RESPIRATORY DISEASES | Novartis AG (CH) | 2006-11-02 | — | — | EP | claimed |
| WO-2005110402-A1 | COMBINATIONS OF GLYCOPYRROLATE AND BETA2 ADRENOCEPTOR AGONISTS | NOVARTIS AG (CH) | 2005-11-24 | — | — | WO | claimed |
| WO-2005074924-A1 | COMBINATION OF BENZOTHIAZOL-2-ONE BETA2 ADRENOCEPTOR AGONISTS AND CORTICOSTEROIDS FOR THE TREATMENT OF RESPIRATORY DISEASES | NOVARTIS AG (CH) | 2005-08-18 | — | — | WO | claimed |
| US-20210236478-A1 | Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists | NOVARTIS AG (CH) | 2021-08-05 | — | — | US | disclosed |
| US-20190282561-A1 | Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists | NOVARTIS AG (CH) | 2019-09-19 | — | — | US | disclosed |
| US-20180071276-A1 | Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists | NOVARTIS AG (CH) | 2018-03-15 | — | — | US | disclosed |
| US-20160101097-A1 | Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists | NOVARTIS AG (CH) | 2016-04-14 | — | — | US | disclosed |
| US-20150065490-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2015-03-05 | — | — | US | disclosed |
| US-20130237564-A1 | Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists | NOVARTIS AG (CH) | 2013-09-12 | — | — | US | disclosed |
| US-20080267886-A1 | Such as 8-hydroxy-5-[1-hydroxy-2-(indan-2-ylamino)-ethyl]-1H-quinolin-2-one; for treatment of inflammatory or obstructive airways diseases | NOVARTIS AG (CH) | 2008-10-30 | — | — | US | disclosed |
| US-20070249586-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | CUENOUD BERNARD | 2007-10-25 | — | — | US | disclosed |
| EP-1755590-A1 | COMBINATIONS OF GLYCOPYRROLATE AND BETA2 ADRENOCEPTOR AGONISTS | Novartis AG (CH) | 2007-02-28 | — | — | EP | disclosed |
| EP-1715860-A1 | COMBINATION OF BENZOTHIAZOL-2-ONE BETA2 ADRENOCEPTOR AGONISTS AND CORTICOSTEROIDS FOR THE TREATMENT OF RESPIRATORY DISEASES | Novartis AG (CH) | 2006-11-02 | — | — | EP | disclosed |
| US-20060106075-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | NOVARTIS AG (CH) | 2006-05-18 | — | — | US | disclosed |
| WO-2005110402-A1 | COMBINATIONS OF GLYCOPYRROLATE AND BETA2 ADRENOCEPTOR AGONISTS | NOVARTIS AG (CH) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005074924-A1 | COMBINATION OF BENZOTHIAZOL-2-ONE BETA2 ADRENOCEPTOR AGONISTS AND CORTICOSTEROIDS FOR THE TREATMENT OF RESPIRATORY DISEASES | NOVARTIS AG (CH) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180071276-A1 | Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists | ADRB2, GALR2, GALR3 | ADRB2 1/4885ADRB1 5/4885DRD3 484/4885 |
| US-20160101097-A1 | Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists | ADRB2, GALR2, GALR3 | ADRB2 1/4885ADRB1 5/4885DRD3 466/4885 |
| US-20210236478-A1 | Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists | ADRB2, GALR2, GALR3 | ADRB2 1/4885ADRB1 5/4885DRD3 462/4885 |
| US-20070249586-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | ADRB2, ADRB1, ADRA2C | ADRB2 1/4885ADRB1 2/4885DRD3 711/4885 |
| US-20190282561-A1 | Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists | ADRB2, GALR2, GALR3 | ADRB2 1/4885ADRB1 6/4885DRD3 532/4885 |
| US-20060106075-A1 | Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity | ADRB2, ADRB1, ADRA2C | ADRB2 1/4885ADRB1 2/4885DRD3 711/4885 |
| US-20080267886-A1 | Such as 8-hydroxy-5-[1-hydroxy-2-(indan-2-ylamino)-ethyl]-1H-quinolin-2-one; for treatment of inflammatory or obstructive airways diseases | GALR1, GALR3, GALR2 | ADRB2 94/4885ADRB1 109/4885DRD3 1497/4885 |
| US-20130237564-A1 | Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists | ADRB2, GALR2, GALR3 | ADRB2 1/4885ADRB1 5/4885DRD3 484/4885 |
| US-20150065490-A1 | ORGANIC COMPOUNDS | ADRB2, ADRA2C, ADRB1 | ADRB2 1/4885ADRB1 3/4885DRD3 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.